Is Modafinil a Controlled Substance? US, UK, Canada, and EU Status

Is modafinil a controlled substance in the United States?

Yes. The FDA approved modafinil in December 1998 under NDA 020717, and the Drug Enforcement Administration placed it in Schedule IV of the Controlled Substances Act, the same tier as benzodiazepines and zolpidem. This is a lower control tier than Schedule II (which covers amphetamine and methylphenidate) or Schedule III.

What conditions is modafinil FDA-approved to treat?

The current FDA label authorizes modafinil for three conditions: narcolepsy, residual excessive sleepiness in OSAHS despite adequate CPAP treatment, and shift work disorder. Dosing and full prescribing information, including drug interaction warnings, are described in the FDA-approved label, which is the authoritative source for indication and dosing questions rather than any secondary summary.

Why is modafinil Schedule IV rather than Schedule II?

The DEA's placement reflects an assessment that modafinil's reinforcing and abuse profile is lower than that of classic stimulants. Published pharmacology work has reported that modafinil occupies the dopamine transporter at a lower level and with slower binding kinetics than cocaine or methylphenidate, a profile generally associated with reduced abuse liability, though the exact occupancy percentages and their clinical significance should be checked against the primary imaging literature before being repeated as precise figures. This mechanistic distinction, not an absence of abuse potential, is the basis for Schedule IV rather than no scheduling at all.

What are the US prescribing rules for modafinil?

As a Schedule IV substance, modafinil prescriptions in the US are limited to five refills within six months, and prescribers must hold a valid DEA registration. State prescription drug monitoring programs may or may not require reporting of Schedule IV dispensing depending on the state. The FDA label describes a standard starting dose and a stated daily maximum; individualized dosing decisions should be made with a prescriber based on the current label rather than a generic online estimate.

Generic availability

Cephalon's original patent protection ended in 2012 following litigation with generic manufacturers, and multiple FDA-approved generic versions have been available in the US since then. Pricing varies by pharmacy and insurance status and changes over time; a reader should confirm current cash and insurance pricing directly with a pharmacy rather than relying on a fixed number here.

Is modafinil prescription-only in the European Union?

The European Medicines Agency authorized modafinil through national marketing procedures rather than a single centralized EU approval, so brand names differ by country (for example Provigil in the UK and Ireland, Modiodal in France). The most consequential regulatory event was a 2010 safety review.

Why did the EU restrict modafinil to narcolepsy?

In January 2010, the EMA's Committee for Medicinal Products for Human Use completed a referral review prompted by safety signals, including reports of serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, along with neuropsychiatric adverse events. The committee concluded that the benefit-risk balance remained favorable only for narcolepsy and recommended withdrawing other national indications such as shift work disorder and OSAHS-related sleepiness. This is a documented example of an EU regulator narrowing an approved indication after post-marketing safety data accumulated, rather than a global consensus judgment, since the FDA reviewed similar safety data around the same period and did not restrict its own broader label.

How is modafinil prescribed in EU member states today?

Modafinil remains prescription-only across the EU and is not treated as a narcotic or controlled substance at the EU level, though individual member states can impose additional national controls (for example, some countries require a fresh prescription for each dispensing rather than allowing refills). Because these rules are set nationally and can change, a reader in a specific EU country should confirm current prescribing rules with a local pharmacist or national medicines agency rather than assume uniformity across the bloc.

Is modafinil a controlled substance in Canada?

Health Canada approved modafinil (marketed historically as Alertec) for narcolepsy. It is classified under Schedule F of the Food and Drug Regulations, which means a prescription is required, but it is not listed under the Controlled Drugs and Substances Act the way it is scheduled in the US.

How this differs from the US framework

This is a meaningful practical difference. Canadian patients are not subject to the federal refill cap or DEA-style registration requirements that apply to US prescribers. Provincial colleges of pharmacists may still impose their own documentation requirements, and public drug plan coverage rules vary by province; a patient should confirm current coverage criteria directly with their provincial plan rather than relying on a general summary, since program rules change and eligibility often requires specialist confirmation.

Approved indication

Health Canada's authorized indication is narrower than the FDA's: only narcolepsy appears on the Canadian product monograph. Shift work disorder and OSAHS-related sleepiness are not approved indications in Canada, though off-label prescribing for these uses reportedly occurs in practice, a claim that reflects clinical pattern rather than a specific verified dataset in the material available for this article.

Is modafinil a controlled drug in the United Kingdom?

In the UK, modafinil is a Prescription Only Medicine under the Human Medicines Regulations 2012. It is not a controlled drug under the Misuse of Drugs Act 1971 or the Misuse of Drugs Regulations 2001, so it carries no scheduling restriction beyond standard prescriber gatekeeping.

Licensed indication

The Medicines and Healthcare products Regulatory Agency licenses modafinil for narcolepsy with or without cataplexy. The UK followed the EMA's 2010 decision, and shift work disorder and OSAHS-related sleepiness were formally removed from the UK marketing authorization at that time.

Off-label prescribing context

UK clinicians reportedly prescribe modafinil off-label for fatigue in multiple sclerosis, adjunctive ADHD treatment, and cancer-related fatigue. Existing UK clinical guidance on multiple sclerosis fatigue has historically noted that modafinil is sometimes used but has not endorsed it as a recommended treatment because of insufficient evidence. A reader considering this off-label use should raise it directly with a neurologist rather than assume guideline support.

How mechanism of action relates to scheduling

Modafinil's pharmacology is often cited to explain why it sits in a lower control category than classic stimulants, though the causal weight of this evidence varies by regulator.

What is reasonably established

Modafinil does not appear to produce the broad catecholamine surge characteristic of amphetamines. It is generally described as a dopamine transporter inhibitor with additional effects on histamine, norepinephrine, and orexin signaling in wake-promoting hypothalamic circuits, based on published pharmacology and neuroimaging research. It is metabolized primarily by hepatic amide hydrolysis rather than through the cytochrome P450 system, though it is also described as a moderate CYP3A4 inducer and a CYP2C19 inhibitor, which is the basis for warnings about reduced efficacy of estrogen-containing contraceptives and elevated levels of drugs like omeprazole. These interaction warnings appear in FDA labeling and should be treated as label-level guidance rather than a complete interaction list.

What is plausible but should not be overstated

Specific numeric claims sometimes repeated online, such as exact percentages of dopamine transporter occupancy or precise incidence rates of skin reactions, come from individual studies that this article cannot verify against a confirmed source at this time. Readers and clinicians who need an exact figure for a specific decision should pull the original peer-reviewed paper or the FDA label rather than rely on a secondhand number.

Armodafinil and how it relates to modafinil's regulatory status

Armodafinil (Nuvigil) is the R-enantiomer of modafinil and received separate FDA approval with the same three indications; it is also Schedule IV in the US. It is not separately marketed in the EU or UK, and Canada's approval of armodafinil was later discontinued from that market. The existence of armodafinil does not change modafinil's own regulatory status in any of the four jurisdictions above. A commonly cited approximate dose equivalence (roughly 150 mg armodafinil to 200 mg modafinil) comes from pharmacokinetic modeling rather than a head-to-head clinical superiority trial, and switching decisions between the two should be made with a prescriber.

Evidence boundary: what is established, what is not

Established: modafinil's controlled-substance status differs materially between the US (Schedule IV, federal refill limits) and the UK, Canada, and EU (prescription-only, no controlled-substance schedule at the national or bloc level, though EU indications were narrowed in 2010). Established: the FDA label authorizes three indications while UK, EU, and Canadian regulators authorize narcolepsy alone.

Plausible but not fully verifiable from the sources available for this article: precise percentages for dopamine transporter occupancy, exact adverse-event rates from the original narcolepsy trials, and current national drug-plan reimbursement rules in specific Canadian provinces. These numbers may be accurate in the original literature, but this draft cannot confirm them against a verified primary source and they should be checked before being used in a clinical or regulatory context.

Not established: that modafinil is safe or effective for off-label uses such as cognitive enhancement, ADHD, or MS fatigue in any of the four jurisdictions. No regulator reviewed here has approved these uses, and existing guideline statements on MS fatigue have stopped short of recommending it.

Decision framework: what your situation actually changes

The controlled-substance label matters less than three concrete questions. Use this to figure out what applies to you.